For example, a retrospective study found longer progression-free survival (PFS) for patients with pancreatic cancer and non-BRCA HR gene mutations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RAD51D, RTEL1) compared to patients without a known HR mutation when treated with platinum chemotherapy [43]. The gene discussed is CHEK2; the disease is familial pancreatic carcinoma.